An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats
Tarek A Ahmed,1,2 Mohammed A Mussari,1 Seham El-Sayed Abdel-Hady,1 Khalid M El-Say1,2 1Department Of Pharmaceutics, Faculty Of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department Of Pharmaceutics And Industrial Pharmacy, Faculty Of Pharmacy, Al-Azhar University, Cairo 1...
Main Authors: | Ahmed TA, Mussari MA, Abdel-Hady SES, El-Say KM |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/an-optimized-surfactant-based-peg-plcl-in-situ-gel-formulation-for-enh-peer-reviewed-article-DDDT |
Similar Items
-
Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo
by: Yinhui Liu, et al.
Published: (2018-03-01) -
A comparative study of atorvastatin and rosuvastatin on lipid lowering efficacy in hyperlipidemic patients
by: Samia Haque Tonu, et al.
Published: (2018-03-01) -
Rosuvastatin and ellagic acid protect against isoproterenol-induced myocardial infarction in hyperlipidemic rats
by: Mai A. Elhemely, et al.
Published: (2014-12-01) -
Rosuvastatin Affects Tracheal Responsiveness, Bronchoalveolar Lavage Inflammatory Cells, and Oxidative Stress Markers in Hyperlipidemic and Asthmatic Rats
by: Saeideh Saadat, et al.
Published: (2019-10-01) -
New hypolipidemic drugs from the group of reductase inhibitors GMG-CoA
by: A V Susekov, et al.
Published: (2003-02-01)